MedTrace Logo

Intranasal INNA-051 for Prevention of COVID-19 in Adults

NCT05118763 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-04-14

No results posted yet for this study

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Conditions

  • COVID-19 Pandemic

Interventions

DRUG

INNA-051

Liquid for intranasal administration

OTHER

Placebo

Liquid for intranasal administration

Sponsors & Collaborators

  • ENA Respiratory Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05118763 on ClinicalTrials.gov